Disease | scleroderma |
Symptom | C0037274|skin disease |
Sentences | 2 |
PubMedID- 21572795 | The primary outcome is the change in the modified rodnan skin score (a standard outcome measure for skin disease in patients with scleroderma that is calculated by summation of skin thicknesses in 17 body sites) from baseline to 4 months. |
PubMedID- 21378404 | Conclusions: mmf may benefit skin disease in patients with diffuse scleroderma, but prospective studies are required to determine its role. |
Page: 1